HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 13,416 shares, a decrease of 78.6% from the December 15th total of 62,738 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily trading volume, of 65,324 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 65,324 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.8% of the company’s stock are short sold.

Institutional Investors Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Golden State Wealth Management LLC bought a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned about 0.69% of HCW Biologics at the end of the most recent quarter. Institutional investors and hedge funds own 2.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, HCW Biologics has a consensus rating of “Hold” and an average target price of $35.00.

HCW Biologics Stock Performance

NASDAQ HCWB traded down $0.05 during trading hours on Wednesday, hitting $1.15. The company had a trading volume of 16,928 shares, compared to its average volume of 45,125. The business has a 50 day moving average of $1.90 and a 200-day moving average of $3.44. The company has a market cap of $3.77 million, a PE ratio of -0.10 and a beta of 0.71. HCW Biologics has a 1-year low of $0.95 and a 1-year high of $41.20.

HCW Biologics (NASDAQ:HCWB) last posted its earnings results on Friday, November 14th. The company reported ($2.02) EPS for the quarter, missing analysts’ consensus estimates of $1.58 by ($3.60). The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $7.00 million.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.